Betaseron Articles
Does the MS market need another Interferon? US neurologists provide insight on the launch of Novartis’ Extavia
12 January 2010
UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease
3 December 2009
Regulatory approval briefs: Betaferon in China; new use for Lilly’s Cymbalta in USA; update on telavancin
1 December 2009
Novartis Multiple sclerosis drug Extavia cleared by US FDA
17 August 2009
Bayer hit by charges and falling material science sales in 1st qtr, but pharma division doing well
29 April 2009
Bayer to launch MS drug in titration pack
27 March 2009
Bayer data encourages early MS treatment
29 September 2008
Bayer's 2nd-qtr 2008 net profit falls 13%
11 August 2008
Correction: Novartis' Extavia
9 June 2008
Approval for Novartis' generic Betaferon in EU
2 June 2008
New Rebif formulation launched in UK
10 March 2008
Bayer's 4th-qtr 2007 profit plummets 76% to 67M euros, well below analyst expectations
10 March 2008
Betaseron linked to fewer injection site reactions
12 November 2007
500mcg Betaferon fails to show result in RRMS
5 November 2007
Bayer and Novartis biologics deal closes
24 September 2007
Early Betaferon use cuts MS disability risk
13 August 2007
Biogen's Avonex: most cost-effective INF-beta
23 April 2007
Betaferon NAbs not key to poor clinical response
16 April 2007
Stock Commentary - Europe - week to April 2
9 April 2007
Stock Commentary - Europe - week to March 26
2 April 2007
Bayer and Novartis in MS drug deal
2 April 2007
Stock Commentary - Europe - week to Jan 15, 2007
22 January 2007
Schering AG buy boosts Bayer but charges take toll on profit; 3rd-qtr beats forecasts
4 December 2006
Betaferon OKed in Australia for earliest stages of MS
27 November 2006
Schering AG's Betaferon gets expanded US label
30 October 2006
Betaferon cuts risk of developing MS
9 October 2006
Superior adherence with BI's Avonex
9 October 2006
MS patients on Teva's Copaxone miss less working days
18 September 2006
Teva's Azilect approved for early PD in Canada
28 August 2006
Schering AG's Betaferon cuts risk of clinical MS
28 August 2006
Expanded Canada label for Berlex' Betaferon
14 August 2006
Merck KGAA discontinues sarizotan after drug misses Ph III efficacy endpoints in PADDY-1/2
3 July 2006
16% 1st-qtr 2006 sales rise for Schering AG
24 April 2006
LIFT study: good results for Schering's Betaferon
10 April 2006
Schering AG sees 2005 net leap 23%
27 February 2006
New Zealand funds Teva's MS drug Copaxone
5 December 2005
Schering AG 1st-half profits leap 23%
1 August 2005
Schering AG completes BENEFIT Ph III study in MS
27 June 2005
UPDATE: Biogen and Elan pull MS drug Tysabri from the market on two cases of CNS disorder
7 March 2005
Stock Commentary - Europe
25 October 2004
Schering AG raises 2004 forecast on 2nd-qtr
2 August 2004
Chiron's 2nd-qtr income dips but sales rise
2 August 2004
Stock Commentary - Europe
24 May 2004
Schering AG's 1st-qtr beats expectations
3 May 2004
Stock Commentary - Europe
1 March 2004
UPDATE: Schering AG reports 6% "organic" sales growth for 2003, but conservative outlook
16 February 2004
Schering AG reports 6% "organic" sales growth for 2003
9 February 2004
Schering AG sees strong profit growth
3 November 2003
FDA clears Betaferon pre-filled diluent syringe
20 October 2003
Expanded US label OKed for Betaferon
24 March 2003
Update: Sales up 11% at Schering AG
10 March 2003
Stock Commentary - Week to Feb 17 - Europe
24 February 2003
Autoinjector for Betaferon launched in Germany
24 February 2003
Study questions long-term IFN use in MS
24 February 2003
Schering AG's 2002 sales disappoint
10 February 2003
Schering AG US sales up 22% in Q2
5 August 2002
Prempro fall-out could affect Schering AG
22 July 2002
Pfizer's muscle to support Rebif in USA
15 July 2002
Schering AG's 1st-qtr sales rise 7%
6 May 2002
Biogen hits back at Serono with new study
29 April 2002
Schering AG CEO optimistic about firm's future prospects
22 April 2002
Serono seeks to overturn Berlex patent
25 March 2002
Schering AG starts Betaferon trial early MS
11 March 2002
Net income up 24% at Schering AG as Betaferon sales stay strong
11 February 2002
Chiron Corp 2001 revenues top $1 bill
11 February 2002
FDA approves room-temp formulation of Berlex' Betaseron.
21 January 2002
Rebif panel meeting in USA cancelled
7 January 2002
Rebif panel meeting in USA cancelled
27 December 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
